David C. Marek
Net Worth
Last updated:
What is David C. Marek net worth?
The estimated net worth of Mr. David C. Marek is at least $5,544,132 as of 24 Sep 2025. He has earned $1,189,802 from insider trading and has received compensation worth at least $4,354,330 in Axsome Therapeutics, Inc. and Myovant Sciences Ltd..
What is the salary of David C. Marek?
Mr. David C. Marek salary is $1,310,000 per year as Chief Executive Officer & Director in Myovant Sciences Ltd.. He also receives $424,330 as Chief Commercial Officer in Axsome Therapeutics, Inc..
How old is David C. Marek?
Mr. David C. Marek is 60 years old, born in 1965.
What stocks does David C. Marek currently own?
As insider, Mr. David C. Marek owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Myovant Sciences Ltd. (MYOV) | Chief Executive Officer & Director | 417,599 | $0 | $0 |
What does Myovant Sciences Ltd. do?
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
David C. Marek insider trading
Myovant Sciences Ltd.
Mr. David C. Marek has made 5 insider trades between 2022-2023, according to the Form 4 filled with the SEC. Most recently he sold 8,037 units of MYOV stock worth $216,115 on 18 Jan 2023.
The largest trade he's ever made was exercising 24,594 units of MYOV stock on 19 Apr 2022. As of 24 Sep 2025 he still owns at least 417,599 units of MYOV stock.
Axsome Therapeutics key executives
Axsome Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Amanda Jones Pharm.D. Senior Vice President of Clinical Research
- Dr. Cedric O'Gorman M.B.A., M.D., MBA Senior Vice President of Clinical Devel. & Medical Affairs
- Dr. Herriot Tabuteau M.D. (57) Founder, Chairman, Chief Executive Officer & Pres
- Joseph Debrah-Afful CPA, M.B.A. Director of Fin.
- Mr. David C. Marek (60) Chief Commercial Officer
- Mr. Mark L. Jacobson Chief Operating Officer & Sec.
- Mr. Nick Pizzie CPA, M.B.A. (50) Chief Financial Officer